Securities code: 600671 securities abbreviation: St target drug Announcement No.: pro 2022-012
Hangzhou Tianmushan Pharmaceutical Enterprise Co.Ltd(600671)
Correction announcement on election of chairman and vice chairman, adjustment of special committee and change of legal representative
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear individual and joint liabilities for the authenticity, accuracy and completeness of its contents. Hangzhou Tianmushan Pharmaceutical Enterprise Co.Ltd(600671) (hereinafter referred to as “the company”) disclosed the announcement on the election of chairman, vice chairman, adjustment of special committee and change of legal representative (Announcement No.: pro 2022-010) on February 15, 2022. Due to the negligence of staff, the announcement is corrected as follows:
1. Special Committee of the board of directors
Before correction: after this by election, the composition of the strategy committee of the 11th board of directors is as follows:
Convener and member of the special committee
Li Feng, Peiyang, Zhao Xiang, strategy committee of the 11th board of directors
After correction: after this by election, the composition of the strategy committee of the 11th board of directors is as follows:
Convener and member of the special committee
Li Feng, Dang Guojun, Zhao Xiang, strategy committee of the 11th board of directors
2. Resume of chairman and vice chairman
Resume of chairman Li Feng: Li Feng, male, born in July 1977, Chinese nationality, bachelor degree, without long-term residency abroad. From September 1997 to July 2001, studied in Xi’an Vocational and technical school; From September 2001 to January 2003, he was the deputy leader of the 12th squadron of Qingdao Armed Police Fire detachment, the officer of the cadre section of Qingdao Fire detachment from January 2003 to January 2010, and the director of the Political Department of Jining public security fire detachment from January 2010 to October 2016. Since January 2017, he has served as executive director, general manager and legal representative of Qingdao shared emergency safety management consulting Co., Ltd. He is currently the executive deputy general manager of the company, the non independent director and chairman of the 11th board of directors of the company.
Yongxin Huarui Cultural Development Co., Ltd. (hereinafter referred to as “Yongxin Huarui”) and its concerted actor Qingdao shared emergency safety management consulting Co., Ltd. (hereinafter referred to as “Qingdao shared”) are now the largest shareholder of the company. Qingdao shared holds 4000028 shares of the company, accounting for 3.28% of the total share capital of the company, and Li Feng holds 50% of the shares of Qingdao shared, Li Feng does not directly hold the shares of the company. In addition to the above relationship, he has no relationship with other shareholders holding more than 5% of the shares of the company. He has not been punished by the CSRC and other relevant departments or the stock exchange.
Resume of Mr. Liu Bo, Vice Chairman: Liu Bo, male, born in January 1975, member of the Communist Party of China, master’s degree, Chinese nationality, without long-term right of residence abroad. Liu Bo has been engaged in drug sales management for a long time. He used to be the office director, general manager assistant and deputy general manager of Shanghai Zhongxi Pharmaceutical Co., Ltd., the general manager assistant and general manager of business division of Shanghai Xinyi Pharmaceutical Co., Ltd., and the deputy general manager of Shanghai Xinya Minhang Pharmaceutical Co., Ltd. He is currently the general manager of Shanghai yimenghui pharmaceutical consulting Co., Ltd., the general manager of Shanghai maipeng Medical Technology Co., Ltd., Hangzhou Tianmushan Pharmaceutical Enterprise Co.Ltd(600671) general manager and Hangzhou Tianmushan Pharmaceutical Enterprise Co.Ltd(600671) the 11th non independent director.
Liu Bo does not hold shares of the company and has no relationship with other directors, supervisors, senior managers and shareholders holding more than 5% of the shares of the company. Liu Bo is not under the circumstances specified in Article 146 of the company law; Not punished by the CSRC and other relevant departments; There is no case of being prohibited from entering the securities market by the CSRC; There is no case that the stock exchange publicly determines that it is not suitable to serve as a director of a listed company.
It is hereby announced.
Hangzhou Tianmushan Pharmaceutical Enterprise Co.Ltd(600671) board of directors
February 16, 2022
